A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...
A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...
At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.
US President's Emergency Plan for AIDS Relief (PEPFAR), the global HIV response has entered a second year of structural ...
A new study has overcome a long-standing challenge: how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results